These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 25484108)

  • 21. Increased levels of Dickkopf-1 are indicative of Wnt/β-catenin downregulation and lower osteoblast signaling in children and adolescents with type 1 diabetes mellitus, contributing to lower bone mineral density.
    Tsentidis C; Gourgiotis D; Kossiva L; Marmarinos A; Doulgeraki A; Karavanaki K
    Osteoporos Int; 2017 Mar; 28(3):945-953. PubMed ID: 27766367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women.
    Fassio A; Adami G; Benini C; Vantaggiato E; Saag KG; Giollo A; Lippolis I; Viapiana O; Idolazzi L; Orsolini G; Rossini M; Gatti D
    Bone; 2019 Jun; 123():191-195. PubMed ID: 30910600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between sclerostin and bone density in chronic spinal cord injury.
    Morse LR; Sudhakar S; Danilack V; Tun C; Lazzari A; Gagnon DR; Garshick E; Battaglino RA
    J Bone Miner Res; 2012 Feb; 27(2):352-9. PubMed ID: 22006831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The relationship between inhibitors of the Wnt signalling pathway (sclerostin and Dickkopf-1) and carotid intima-media thickness in postmenopausal women with type 2 diabetes mellitus.
    Gaudio A; Privitera F; Pulvirenti I; Canzonieri E; Rapisarda R; Fiore CE
    Diab Vasc Dis Res; 2014 Jan; 11(1):48-52. PubMed ID: 24227537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum levels of the bone turnover markers dickkopf-1, sclerostin, osteoprotegerin, osteopontin, osteocalcin and 25-hydroxyvitamin D in Swedish geriatric patients aged 75 years or older with a fresh hip fracture and in healthy controls.
    Wanby P; Nobin R; Von SP; Brudin L; Carlsson M
    J Endocrinol Invest; 2016 Aug; 39(8):855-63. PubMed ID: 26850415
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss.
    Gaudio A; Pennisi P; Bratengeier C; Torrisi V; Lindner B; Mangiafico RA; Pulvirenti I; Hawa G; Tringali G; Fiore CE
    J Clin Endocrinol Metab; 2010 May; 95(5):2248-53. PubMed ID: 20305005
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Anastasilakis AD; Kountouras J; Makras P; Papatheodorou A; Kokkoris P; Sakellariou GT; Terpos E
    J Bone Miner Metab; 2016 Jul; 34(4):447-56. PubMed ID: 26056025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness.
    Thambiah S; Roplekar R; Manghat P; Fogelman I; Fraser WD; Goldsmith D; Hampson G
    Calcif Tissue Int; 2012 Jun; 90(6):473-80. PubMed ID: 22527202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppression of Sclerostin and Dickkopf-1 levels in patients with fluorine bone injury.
    Wang W; Xu J; Liu K; Liu X; Li C; Cui C; Zhang Y; Li H
    Environ Toxicol Pharmacol; 2013 May; 35(3):402-7. PubMed ID: 23467116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum extracellular secreted antagonists of the canonical Wnt/β-catenin signaling pathway in patients with Cushing's syndrome.
    Belaya ZE; Rozhinskaya LY; Melnichenko GA; Solodovnikov AG; Dragunova NV; Iljin AV; Dzeranova LK; Dedov II
    Osteoporos Int; 2013 Aug; 24(8):2191-9. PubMed ID: 23358608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Distinct effect of zoledronate and clodronate on circulating levels of DKK1 and sclerostin in women with postmenopausal osteoporosis.
    Gatti D; Viapiana O; Idolazzi L; Fracassi E; Ionescu C; Dartizio C; Troplini S; Kunnathully V; Adami S; Rossini M
    Bone; 2014 Oct; 67():189-92. PubMed ID: 25003812
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sclerostin Antibody Reverses the Severe Sublesional Bone Loss in Rats After Chronic Spinal Cord Injury.
    Zhao W; Li X; Peng Y; Qin Y; Pan J; Li J; Xu A; Ominsky MS; Cardozo C; Feng JQ; Ke HZ; Bauman WA; Qin W
    Calcif Tissue Int; 2018 Oct; 103(4):443-454. PubMed ID: 29931461
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Periostin and sclerostin levels in individuals with spinal cord injury and their relationship with bone mass, bone turnover, fracture and osteoporosis status.
    Maïmoun L; Ben Bouallègue F; Gelis A; Aouinti S; Mura T; Philibert P; Souberbielle JC; Piketty M; Garnero P; Mariano-Goulart D; Fattal C
    Bone; 2019 Oct; 127():612-619. PubMed ID: 31351195
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biomarkers of bone metabolism in ankylosing spondylitis in relation to osteoproliferation and osteoporosis.
    Klingberg E; Nurkkala M; Carlsten H; Forsblad-d'Elia H
    J Rheumatol; 2014 Jul; 41(7):1349-56. PubMed ID: 24931960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation of blood bone turnover biomarkers and Wnt signaling antagonists with AS, DISH, OPLL, and OYL.
    Niu CC; Lin SS; Yuan LJ; Chen LH; Yang CY; Chung AN; Lu ML; Tsai TT; Lai PL; Chen WJ
    BMC Musculoskelet Disord; 2017 Feb; 18(1):61. PubMed ID: 28153008
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High serum levels of sclerostin and Dickkopf-1 are associated with acute ischaemic stroke.
    He XW; Wang E; Bao YY; Wang F; Zhu M; Hu XF; Jin XP
    Atherosclerosis; 2016 Oct; 253():22-28. PubMed ID: 27573735
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of serum myostatin and sclerostin levels in chronic spinal cord injured patients.
    Invernizzi M; Carda S; Rizzi M; Grana E; Squarzanti DF; Cisari C; Molinari C; Renò F
    Spinal Cord; 2015 Aug; 53(8):615-20. PubMed ID: 25896346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of Wnt-signaling inhibitors DKK-1 and sclerostin in bone fragility associated with Turner syndrome.
    Chiarito M; Piacente L; Chaoul N; Pontrelli P; D'Amato G; Grandone A; Russo G; Street ME; Wasniewska MG; Brunetti G; Faienza MF
    J Endocrinol Invest; 2022 Jun; 45(6):1255-1263. PubMed ID: 35237949
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sclerostin and DKK1 in primary hyperparathyroidism.
    Viapiana O; Fracassi E; Troplini S; Idolazzi L; Rossini M; Adami S; Gatti D
    Calcif Tissue Int; 2013 Apr; 92(4):324-9. PubMed ID: 23430197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In psoriatic arthritis Dkk-1 and PTH are lower than in rheumatoid arthritis and healthy controls.
    Fassio A; Idolazzi L; Viapiana O; Benini C; Vantaggiato E; Bertoldo F; Rossini M; Gatti D
    Clin Rheumatol; 2017 Oct; 36(10):2377-2381. PubMed ID: 28634697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.